Northwell Health and Cold Spring Harbor Laboratory open virtual COVID-19 clinical trial for non-hospitalized patients

An outpatient, digital, randomized clinical trial will look at the safety and efficacy of famotidine (PEPCID) to treat mild to moderate Covid-19

MANHASSET, N.Y.–(BUSINESS WIRE)–The Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory (CSHL) are recruiting patients in a fully virtual, in-home, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of famotidine, or PEPCID, for the outpatient treatment of the novel coronavirus disease 2019 (COVID-19) in adults. Sold over-the-counter as PEPCID, famotidine is a histamine 2 blocker used to decrease stomach acid and this clinical trial will assess its use as a COVID-19 therapy.

This is the first time an entirely virtual clinical trial has been initiated by CSHL and Northwell Health, New York’s largest health system, which has treated more than 100,000 COVID-19 patients since the start of the pandemic in March 2020. The trial is recruiting patients across the greater New York area who have tested positive for COVID-19, but are experiencing only mild to moderate symptoms that do not require hospitalization.

For those who qualify, and once consented, patients will be trained to use a cellular activated Apple iPad from their home, along with a Bluetooth enabled scale, thermometer, fitness tracker, spirometer (to study air flow in and out of the lungs), thermometer and pulse oximeter (to measure blood oxygen levels). Placebo or famotidine at 240 mg per day will be prescribed, and taken orally, for a maximum of 14 days. Northwell’s Home Lab program will be utilized for required blood draws and COVID-19 diagnostic nasal swabs tests. This trial is designed to keep trial participants completely out of the hospital throughout the course of their treatment.

“From the comfort of these patients’ own homes, we are taking the traditional clinical trial completely digital to study the efficacy and safety of a potential COVID-19 therapy,” said Tobias Janowitz, MD, PhD, a medical oncologist, principal investigator of the trial, assistant professor at CSHL, and adjunct professor at the Feinstein Institutes. “From assessment, to enrollment and daily data collection, we hope this study’s model will be an example for future clinical trials, and will provide high quality data as we assess candidate treatments, like famotidine, to curb this disease.”

For those interested to learn more about the outpatient famotidine clinical trial, please email

Famotidine is a common, safe over-the-counter drug used to treat heartburn and assist with healing gastrointestinal ulcers. In April 2020, the Feinstein Institutes started the nation’s first famotidine clinical trial, which enrolled more than 230 patients. The initiation of the clinical trial was based on anecdotal reports from China that patients taking the drug had better outcomes from COVID-19.

“It’s been more than a year since this pandemic has spread across the globe, and there is only one fully-authorized COVID-19 therapeutic,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “This innovative clinical trial of patients in their own homes should provide important data to determine if a safe and inexpensive drug may be useful for COVID-19 patients.”

At the start of the pandemic the Feinstein Institutes established a COVID-19 Clinical Trial Unit (CCTU), a 200-member rapid-response clinical trial group of scientists, physicians, administrators and staff to review and launch clinical trials. Since March, the CCTU has enrolled patients in more than seven clinical trials and programs – including famotidine, remdesivir, sarilumab and convalescent plasma. Overall, more than 1,200 patients were enrolled into COVID-19 research trials across the health system, resulting in more than 200 manuscripts published, providing guidance to clinicians worldwide.

The outpatient famotidine trial has been funded by the Fast Grant and Pershing Square Foundation.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.

About Northwell Health

Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, nearly 800 outpatient facilities and more than 14,200 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 74,000 employees – 18,500 nurses and 4,500 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program annually hosts more than 12,000 scientists. The Laboratory’s education arm also includes an academic publishing house, a graduate school and the DNA Learning Center with programs for middle and high school students and teachers. CSHL has been a National Cancer Institute designated cancer center since 1987. For more information, visit


Matthew Libassi


error: Content is protected !!